Short term ex-vivo expansion of circulating head and neck tumour cells
Metrics: PDF 2280 views | HTML 2876 views | ?
Arutha Kulasinghe1,7, Chris Perry2, Majid E. Warkiani3, Tony Blick1,7, Anthony Davies4,7, Ken O'Byrne4,7, Erik W. Thompson1,7, Colleen C. Nelson5,7, Ian Vela5,6,7, Chamindie Punyadeera1,7
1The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia
2Department of Otolaryngology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
3School of Mechanical and Manufacturing Engineering, Australian Centre for NanoMedicine, University of New South Wales, Sydney, Australia
4Translational Cell Imaging Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, QLD, Australia
5Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, QLD, Australia
6Department of Urology, Princess Alexandra Hospital, Wolloongabba, QLD, Australia
7Translational Research Institute, Woolloongabba, QLD, Australia
Chamindie Punyadeera, email: email@example.com
Keywords: circulating tumour cells, head and neck cancer, ex-vivo culture, metastasis, HPV
Received: June 03, 2016 Accepted: July 20, 2016 Published: August 09, 2016
Minimally invasive techniques are required for the identification of head and neck cancer (HNC) patients who are at an increased risk of metastasis, or are not responding to therapy. An approach utilised in other solid cancers is the identification and enumeration of circulating tumour cells (CTCs) in the peripheral blood of patients. Low numbers of CTCs has been a limiting factor in the HNC field to date. Here we present a methodology to expand HNC patient derived CTCs ex-vivo. As a proof of principle study, 25 advanced stage HNC patient bloods were enriched for circulating tumour cells through negative selection and cultured in 2D and 3D culture environments under hypoxic conditions (2% O2, 5% CO2). CTCs were detected in 14/25 (56%) of patients (ranging from 1–15 CTCs/5 mL blood). Short term CTC cultures were successfully generated in 7/25 advanced stage HNC patients (5/7 of these cultures were from HPV+ patients). Blood samples from which CTC culture was successful had higher CTC counts (p = 0.0002), and were predominantly from HPV+ patients (p = 0.007). This is, to our knowledge, the first pilot study to culture HNC CTCs ex-vivo. Further studies are warranted to determine the use of short term expansion in HNC and the role of HPV in promoting culture success.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.